REFERENCES
- Deuter CM, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2016;Jan 5:1–6. DOI:10.3109/09273948.2015.1099680
- Mesquida M, Molins B, Llorenç V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380–6.
- Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95–100.
- Suhler EB, Giles TR, Lin P, et al. An open-label trial to assess the efficacy and safety of tocilizumab in the management of juvenile idiopathic arthritis-associated uveitis: preliminary results. Invest Ophthalmol Vis Sci. 2015;56:860.
- Mitchel EL, Jones G. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2016;Jan 28:1–12.
- Schmidt M, Matsumoto Y, Tisdale A, et al. Optimized intravitreal IL-6 antagonist for the treatment of diabetic macular edema. Invest Ophthalmol Vis Sci. 2015;56:3488.